OCTO Revolutionizes Vehicle Safety with AI: Introducing the Proactive and Predictive Anti-Theft System
10.12.2025 11:00:00 EET | Business Wire | Press release
Anticipating a theft before it happens. This is the goal of OCTO’s new predictive anti-theft system, developed by the global leader in telematics and data analytics solutions for connected mobility.
The new technology combines artificial intelligence, machine learning, and advanced sensors to deliver real-time, personalized vehicle protection capable of recognizing risk signals before a theft event occurs.
Drawing on more than 22 years of experience and 610 billion kilometers of driving data, the system transforms the paradigm of vehicle security from reactive to proactive.
This approach enables prevention rather than mere response, increasing protection for both private vehicles and corporate fleets.
The main features include:
- Tampering detection: sensors identify attempts to access or remove the devices.
- Abnormal vehicle movement: the system detects vehicle dragging or lifting while the engine is off.
- Loss of connection between the devices installed on the vehicle: when one of the two devices is located and removed by a thief, communication with the second terminal is interrupted and an alert is promptly sent to our control center.
- Driver behavior analysis: an AI model identifies suspicious behavior compared to habitual driving patterns, analyzing driving style, typical routes, and timings.
- Geofencing: OCTO’s system maps all high-risk areas where thefts have historically occurred, as well as suspicious locations such as commercial ports or national borders, alerting the theft monitoring center whenever a vehicle approaches or enters these areas.
The combined and continuous analysis of these parameters makes it possible to dynamically calculate the theft risk level and automatically activate the most effective countermeasures. In case of an alert, the OCTO Operations Center uses the most advanced monitoring, localization, and real-time intervention tools.
Backed by many years of experience managing thousands of theft cases each year, OCTO ensures swift and targeted action, providing continuous support to customers and fleets.
About OCTO
For over 20 years, we have been developing integrated solutions that enable us to support our clients in seizing the opportunities offered by smart mobility and digital transformation. Thanks to an innovative approach based on Artificial Intelligence, we have developed advanced algorithms for accident detection, driving behavior analysis, claims management, and consumption optimization. These solutions allow us to meet the needs of key markets, such as insurance and mobility, with a strong focus on modularity and customization. Our scalable and modular data analytics platform delivers solutions for the Insurtech and mobility markets, helping partner companies transform the way they manage and grow their business.
A robust and purpose-driven ESG strategy ultimately guides our market proposition, focusing on the development of solutions that support the energy transition and data-driven urban planning.
OCTO has profiled 20 million drivers and holds the world’s largest telematics database, based on 610 billion kilometers of driving and over 13 million validated claims. octotelematics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251210636626/en/
Contacts
OCTO Media
Adriana Zambon
Phone +39 339.3995640
press@octotelematics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom